← Back to Search

Information Sharing for Chronic Kidney Disease

N/A
Recruiting
Led By Navdeep Tangri, MD PhD FRCPC
Research Sponsored by University of Manitoba
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All patients with CKD Stages G3-G5 who attend the 32 clinics.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months after intervention
Awards & highlights

Summary

This trial will test whether providing patients with information about their risk of kidney failure improves quality of care, health literacy, and trust in the care they are receiving.

Who is the study for?
This trial is for adults with moderate to severe chronic kidney disease (CKD Stages G3-G5) who are treated at primary care clinics in Manitoba and Alberta that use an electronic medical record system capable of integrating the kidney failure risk equation (KFRE).
What is being tested?
The study tests if providing personalized information about kidney failure risk, alongside usual care, improves patient care. Clinics will either integrate this approach or continue with standard care without personalized risk info.
What are the potential side effects?
Since this intervention involves knowledge translation rather than medication, traditional side effects aren't expected. However, there may be impacts on patients' emotional well-being due to awareness of their CKD progression risks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have chronic kidney disease between stages 3 to 5.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months after intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months after intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of CKD patients in each clinic who have albuminuria (albumin-creatinine ratio (ACR)) tested
The percentage of patients who are appropriately managed with an ACEi or ARB, and who either have CKD and diabetes, or who have CKD and a urine ACR >30 mg/mmol.
Secondary study objectives
Appropriate medication usage
Appropriate referral for patients at high risk for kidney failure
Clinical provider's satisfaction with the risk prediction tools and clinical decision aids.
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Active Knowledge Translation GroupExperimental Treatment1 Intervention
Primary care clinics receiving the active knowledge translation intervention.
Group II: Control GroupActive Control1 Intervention
Primary care clinics receiving the current standard of care. Information on personalized risk and risk-based referral will not be provided.

Find a Location

Who is running the clinical trial?

Canadian Primary Care Sentinel Surveillance NetworkUNKNOWN
University of ManitobaLead Sponsor
612 Previous Clinical Trials
195,254 Total Patients Enrolled
Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney DiseaseOTHER
1 Previous Clinical Trials
2,500 Total Patients Enrolled

Media Library

Active Knowledge Translation Clinical Trial Eligibility Overview. Trial Name: NCT03365063 — N/A
Chronic Kidney Disease Research Study Groups: Active Knowledge Translation Group, Control Group
Chronic Kidney Disease Clinical Trial 2023: Active Knowledge Translation Highlights & Side Effects. Trial Name: NCT03365063 — N/A
Active Knowledge Translation 2023 Treatment Timeline for Medical Study. Trial Name: NCT03365063 — N/A
~900 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top